RU2012114190A - Полученный из пробиотиков нежизнеспособный материал для профилактики и лечения аллергии - Google Patents
Полученный из пробиотиков нежизнеспособный материал для профилактики и лечения аллергии Download PDFInfo
- Publication number
- RU2012114190A RU2012114190A RU2012114190/10A RU2012114190A RU2012114190A RU 2012114190 A RU2012114190 A RU 2012114190A RU 2012114190/10 A RU2012114190/10 A RU 2012114190/10A RU 2012114190 A RU2012114190 A RU 2012114190A RU 2012114190 A RU2012114190 A RU 2012114190A
- Authority
- RU
- Russia
- Prior art keywords
- composition
- lgg
- phase
- culture
- composition according
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims abstract 3
- 239000000463 material Substances 0.000 title claims 2
- 230000007815 allergy Effects 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 230000000529 probiotic effect Effects 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 31
- 238000000034 method Methods 0.000 claims abstract 8
- 239000012228 culture supernatant Substances 0.000 claims abstract 6
- 230000005526 G1 to G0 transition Effects 0.000 claims abstract 4
- 239000001963 growth medium Substances 0.000 claims abstract 4
- 102000004169 proteins and genes Human genes 0.000 claims abstract 4
- 108090000623 proteins and genes Proteins 0.000 claims abstract 4
- 238000012365 batch cultivation Methods 0.000 claims abstract 3
- 239000004615 ingredient Substances 0.000 claims abstract 3
- 239000006228 supernatant Substances 0.000 claims abstract 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims abstract 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims abstract 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000005642 Oleic acid Substances 0.000 claims abstract 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims abstract 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims abstract 2
- 235000019486 Sunflower oil Nutrition 0.000 claims abstract 2
- 208000026935 allergic disease Diseases 0.000 claims abstract 2
- 238000010923 batch production Methods 0.000 claims abstract 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000000944 linseed oil Substances 0.000 claims abstract 2
- 235000021388 linseed oil Nutrition 0.000 claims abstract 2
- 239000007788 liquid Substances 0.000 claims abstract 2
- 239000002609 medium Substances 0.000 claims abstract 2
- 230000007935 neutral effect Effects 0.000 claims abstract 2
- 239000003921 oil Substances 0.000 claims abstract 2
- 235000019198 oils Nutrition 0.000 claims abstract 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims abstract 2
- 235000021313 oleic acid Nutrition 0.000 claims abstract 2
- 239000004006 olive oil Substances 0.000 claims abstract 2
- 235000008390 olive oil Nutrition 0.000 claims abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 claims abstract 2
- 239000002600 sunflower oil Substances 0.000 claims abstract 2
- 239000000047 product Substances 0.000 claims 8
- 235000005911 diet Nutrition 0.000 claims 5
- 230000000378 dietary effect Effects 0.000 claims 5
- 235000016709 nutrition Nutrition 0.000 claims 5
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims 4
- 230000000737 periodic effect Effects 0.000 claims 3
- 235000018102 proteins Nutrition 0.000 claims 3
- 235000021342 arachidonic acid Nutrition 0.000 claims 2
- 229940114079 arachidonic acid Drugs 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 claims 2
- 230000035764 nutrition Effects 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 claims 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000975 bioactive effect Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 235000010755 mineral Nutrition 0.000 claims 1
- 229920001542 oligosaccharide Polymers 0.000 claims 1
- 150000002482 oligosaccharides Chemical class 0.000 claims 1
- 235000013406 prebiotics Nutrition 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Композиция для применения в лечении или профилактике аллергических заболеваний, содержащая белковую смесь, причем указанная композиция получена из культурального супернатанта на поздней экспоненциальной фазе процесса периодического культивирования LGG.2. Композиция по п.1, полученная способом, включающим этапы (а) подвергания LGG культивированию в приемлемой культуральной среде с использованием периодического процесса; (b) сбора культурального супернатанта на поздней экспоненциальной фазе этапа культивирования, причем фаза определяется относительно второй половины времени между lag-фазой и стационарной фазой процесса периодического культивирования LGG; (с) необязательно удаления низкомолекулярных составляющих из супернатанта так, чтобы сохранять молекулярную массу составляющих выше 6 кДа; (d) удаления жидкого содержимого из культурального супернатанта для получения композиции.3. Композиция по п.1, где поздняя экспоненциальная фаза определяется относительно последней четверти времени между lag-фазой и стационарной фазой процесса периодического культивирования LGG, предпочтительно 0,75-0,85 времени, истекшего в экспоненциальной фазе.4. Композиция по п.1, где периодическое культивирование LGG выполняется в культуральной среде без Tween 80, среде, необязательно содержащей масляный ингредиент, выбранный из группы, состоящей из олеиновой кислоты, льняного масла, оливкового масла, рапсового масла, подсолнечного масла и их смесей.5. Композиция по п.1, где периодическое культивирование LGG выполняется при нейтральном рН, предпочтительно рН 6, при физиологической температуре, предпочтительно 37°С.6. Композиция по п.1, в сухой ф�
Claims (13)
1. Композиция для применения в лечении или профилактике аллергических заболеваний, содержащая белковую смесь, причем указанная композиция получена из культурального супернатанта на поздней экспоненциальной фазе процесса периодического культивирования LGG.
2. Композиция по п.1, полученная способом, включающим этапы (а) подвергания LGG культивированию в приемлемой культуральной среде с использованием периодического процесса; (b) сбора культурального супернатанта на поздней экспоненциальной фазе этапа культивирования, причем фаза определяется относительно второй половины времени между lag-фазой и стационарной фазой процесса периодического культивирования LGG; (с) необязательно удаления низкомолекулярных составляющих из супернатанта так, чтобы сохранять молекулярную массу составляющих выше 6 кДа; (d) удаления жидкого содержимого из культурального супернатанта для получения композиции.
3. Композиция по п.1, где поздняя экспоненциальная фаза определяется относительно последней четверти времени между lag-фазой и стационарной фазой процесса периодического культивирования LGG, предпочтительно 0,75-0,85 времени, истекшего в экспоненциальной фазе.
4. Композиция по п.1, где периодическое культивирование LGG выполняется в культуральной среде без Tween 80, среде, необязательно содержащей масляный ингредиент, выбранный из группы, состоящей из олеиновой кислоты, льняного масла, оливкового масла, рапсового масла, подсолнечного масла и их смесей.
5. Композиция по п.1, где периодическое культивирование LGG выполняется при нейтральном рН, предпочтительно рН 6, при физиологической температуре, предпочтительно 37°С.
6. Композиция по п.1, в сухой форме, предпочтительно высушенная распылением или высушенная замораживанием.
7. Композиция по п.6, в которой фармацевтически приемлемый материал-носитель, такой как мальтодекстрин DE29, добавляется в супернатант с последующей сушкой распылением.
8. Композиция по любому из пп.1-7 в форме диетического продукта, предпочтительно питательного продукта или добавки для такого продукта, предпочтительно питательного продукта.
9. Композиция по п.8, в которой диетический продукт дополнительно содержит один или несколько полиненасыщенных жирных кислот (PUFA), предпочтительно длинноцепочных полиненасыщенных жирных кислот (LC-PUFA), таких как арахидоновая кислота (ARA) и докозагексаеновая кислота (DHA).
10. Композиция по п.8, в которой диетический продукт дополнительно содержит одно или несколько биоактивных ингредиентов, таких как белки или полисахариды, обычно присутствующих в человеческом грудном молоке.
11. Композиция по п.8, в которой диетический продукт дополнительно содержит один или несколько пребиотиков, предпочтительно выбранных из группы, состоящей из неперевариваемых олигосахаридов, неперевариваемых полисахаридов и их смесей.
12. Композиция по п.8, в которой диетический продукт является смесью для беременных, младенцев или детей, или питательной композицией, или добавкой, лечебным питанием или питанием для специальных медицинских целей.
13. Смесь для младенцев или детей, которая является питательно полноценной в отношении наличия липидов, углеводов, белков, витаминов и минералов, дополнительно включающая композицию по любому из пп.1-7.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170124A EP2295535A1 (en) | 2009-09-11 | 2009-09-11 | Probiotic material |
| EP09170124.3 | 2009-09-11 | ||
| PCT/NL2010/050576 WO2011031149A1 (en) | 2009-09-11 | 2010-09-10 | Probiotic derived non-viable material for allergy prevention and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012114190A true RU2012114190A (ru) | 2013-10-20 |
Family
ID=41561153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012114190/10A RU2012114190A (ru) | 2009-09-11 | 2010-09-10 | Полученный из пробиотиков нежизнеспособный материал для профилактики и лечения аллергии |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20110217402A1 (ru) |
| EP (2) | EP2295535A1 (ru) |
| JP (1) | JP2013504321A (ru) |
| KR (1) | KR20120061836A (ru) |
| CN (1) | CN102575224A (ru) |
| AU (1) | AU2010293145B2 (ru) |
| BR (1) | BR112012005533A2 (ru) |
| CA (1) | CA2772593C (ru) |
| EC (1) | ECSP12011786A (ru) |
| ES (1) | ES2614929T3 (ru) |
| IN (1) | IN2012DN00951A (ru) |
| MX (1) | MX345077B (ru) |
| MY (1) | MY160646A (ru) |
| NZ (1) | NZ597818A (ru) |
| PE (1) | PE20121557A1 (ru) |
| PL (1) | PL2475764T3 (ru) |
| RU (1) | RU2012114190A (ru) |
| SG (1) | SG178230A1 (ru) |
| TW (1) | TWI595090B (ru) |
| WO (1) | WO2011031149A1 (ru) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130095189A1 (en) * | 2011-10-14 | 2013-04-18 | Zeina Jouni | Composition and method of phytonutrients for metabolic programming effects |
| US20130251829A1 (en) * | 2012-03-23 | 2013-09-26 | Mead Johnson Nutrition Company | Probiotic derived non-viable material for infection prevention and treatment |
| US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
| US9345727B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
| US9289461B2 (en) | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
| US8889633B2 (en) * | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
| US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
| US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
| US20150305384A1 (en) * | 2014-04-25 | 2015-10-29 | Mead Johnson Nutrition Company | Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics |
| WO2015177246A2 (en) * | 2014-05-20 | 2015-11-26 | Biogaia Ab | Neonatal microbiome supplementation |
| US9730969B2 (en) | 2015-11-06 | 2017-08-15 | Mead Johnson Nutrition Company | Nutritional compositions for promoting gut barrier function and ameliorating visceral pain |
| US10034937B2 (en) | 2015-12-04 | 2018-07-31 | Mead Johnson Nutrition Company | Synergistic nutritional compositions and uses thereof |
| JP7057059B2 (ja) | 2016-08-22 | 2022-04-19 | 株式会社明治 | ラクトバチルス・プランタラムの培養物の製造方法 |
| US20180064739A1 (en) | 2016-09-06 | 2018-03-08 | Mead Johnson Nutrition Company | Nutritional composition with human milk oligosaccharides and uses thereof |
| US20180103675A1 (en) | 2016-10-14 | 2018-04-19 | Mead Johnson Nutrition Company | Personalized pediatric nutrition products comprising human milk oligosaccharides |
| US20180160714A1 (en) | 2016-12-12 | 2018-06-14 | Mead Johnson Nutrition Company | Nutritional compositions containing butyrate and uses thereof |
| US20180161292A1 (en) | 2016-12-12 | 2018-06-14 | Mead Johnson Nutrition Company | Nutritional compositions containing butyrate and uses thereof |
| US10980269B2 (en) | 2016-12-12 | 2021-04-20 | Mead Johnson Nutrition Company | Protein hydrolysates and methods of making same |
| US20180168215A1 (en) | 2016-12-21 | 2018-06-21 | Mead Johnson Nutrition Company | Nutritional compositions containing inositol and uses thereof |
| US20180333426A1 (en) | 2017-05-17 | 2018-11-22 | Mead Johnson Nutrition Company | Nutritional composition with human milk oligosaccharides and uses thereof |
| US20180332881A1 (en) | 2017-05-17 | 2018-11-22 | Mead Johnson Nutrition Company | Preterm infant formula containing butyrate and uses thereof |
| CA3081560A1 (en) * | 2017-11-07 | 2019-05-16 | Hubit Genomix, Inc. | Method for primary prevention of allergic disorders during infancy through ige-class-specific immunosuppression |
| US20190208807A1 (en) | 2018-01-05 | 2019-07-11 | Mead Johnson Nutrition Company | Nutritional compositions containing milk-derived peptides and uses thereof |
| EP3524051A1 (en) * | 2018-02-12 | 2019-08-14 | DuPont Nutrition Biosciences ApS | Matricial microencapsulation compositions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839281A (en) | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| US5407957A (en) | 1990-02-13 | 1995-04-18 | Martek Corporation | Production of docosahexaenoic acid by dinoflagellates |
| CA2101274C (en) | 1991-01-24 | 1998-12-15 | David J. Kyle | Microbial oil mixtures and uses thereof |
| US5374567A (en) | 1993-05-20 | 1994-12-20 | The United States Of America As Represented By The Secretary Of The Navy | Operational amplifier using bipolar junction transistors in silicon-on-sapphire |
| FI104465B (fi) * | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US6506389B2 (en) | 1995-10-20 | 2003-01-14 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek (Tno) | Adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors |
| US6051552A (en) * | 1996-05-30 | 2000-04-18 | Urex Biotech, Inc. | Lactobacillus therapies |
| EP0904784A1 (en) * | 1997-09-22 | 1999-03-31 | N.V. Nutricia | Probiotic nutritional preparation |
| CA2374937A1 (en) * | 1999-05-25 | 2000-11-30 | Gregor Reid | Oral administration of lactobacillus for the maintenance of health in women |
| AU8455801A (en) | 2000-08-08 | 2002-02-18 | Genesis Res & Dev Corp Ltd | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them |
| US20060057131A1 (en) * | 2001-12-20 | 2006-03-16 | Eric Simard | Malleable protein matrix and uses thereof |
| KR20050094403A (ko) * | 2002-12-13 | 2005-09-27 | 로레알 | 경구 투여로 피부의 피지 기능을 자극하기 위한 조성물제조에서의 카페인 제거 커피 원두 추출물의 용도 |
| US20040208863A1 (en) | 2003-01-30 | 2004-10-21 | James Versalovic | Anti-inflammatory activity from lactic acid bacteria |
| US20070031537A1 (en) * | 2003-06-23 | 2007-02-08 | Marie-Cristene Secretin | Infant or follow-on formula |
| CA2563702A1 (en) * | 2004-04-20 | 2005-12-01 | The University Of Chicago | Probiotic compounds from lactobacillus gg and uses therefor |
| US20100233312A9 (en) * | 2005-04-11 | 2010-09-16 | The Procter & Gamble Company | Compositions comprising probiotic and sweetener components |
| US20060233772A1 (en) * | 2005-04-15 | 2006-10-19 | Udo Herz | Method for preventing or treating the development of respiratory allergies |
| US7303745B2 (en) * | 2005-04-15 | 2007-12-04 | Bristol-Myers Squibb Company | Method for preventing or treating the development of respiratory allergies |
| WO2008052035A1 (en) * | 2006-10-24 | 2008-05-02 | Vanderbilt University | Compositions and methods for the treatment of disorders involving epithelial cell apoptosis |
| AR066016A1 (es) * | 2007-04-11 | 2009-07-15 | Alcon Res Ltd | Uso de un inhibidor del tnf alfa junto con una antihistamina para tratar la rinitis alergica y la conjuntivitis alergica |
| WO2009137159A2 (en) * | 2008-04-17 | 2009-11-12 | Trustees Of Dartmouth College | Bioactive molecules produced by probiotic bacteria and methods for isolating and using the same |
-
2009
- 2009-09-11 EP EP09170124A patent/EP2295535A1/en not_active Ceased
-
2010
- 2010-09-10 AU AU2010293145A patent/AU2010293145B2/en not_active Ceased
- 2010-09-10 RU RU2012114190/10A patent/RU2012114190A/ru not_active Application Discontinuation
- 2010-09-10 PL PL10757324T patent/PL2475764T3/pl unknown
- 2010-09-10 CA CA2772593A patent/CA2772593C/en not_active Expired - Fee Related
- 2010-09-10 CN CN201080040659XA patent/CN102575224A/zh active Pending
- 2010-09-10 EP EP10757324.8A patent/EP2475764B1/en not_active Not-in-force
- 2010-09-10 NZ NZ597818A patent/NZ597818A/en not_active IP Right Cessation
- 2010-09-10 PE PE2012000122A patent/PE20121557A1/es not_active Application Discontinuation
- 2010-09-10 MX MX2012002716A patent/MX345077B/es active IP Right Grant
- 2010-09-10 MY MYPI2012000513A patent/MY160646A/en unknown
- 2010-09-10 US US12/879,136 patent/US20110217402A1/en not_active Abandoned
- 2010-09-10 JP JP2012528768A patent/JP2013504321A/ja active Pending
- 2010-09-10 KR KR1020127003851A patent/KR20120061836A/ko active Search and Examination
- 2010-09-10 TW TW099130665A patent/TWI595090B/zh not_active IP Right Cessation
- 2010-09-10 BR BR112012005533A patent/BR112012005533A2/pt not_active Application Discontinuation
- 2010-09-10 ES ES10757324.8T patent/ES2614929T3/es active Active
- 2010-09-10 IN IN951DEN2012 patent/IN2012DN00951A/en unknown
- 2010-09-10 WO PCT/NL2010/050576 patent/WO2011031149A1/en active Application Filing
- 2010-09-10 SG SG2012007449A patent/SG178230A1/en unknown
-
2012
- 2012-04-05 EC ECSP12011786 patent/ECSP12011786A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2772593C (en) | 2018-11-27 |
| KR20120061836A (ko) | 2012-06-13 |
| PL2475764T3 (pl) | 2017-06-30 |
| EP2295535A1 (en) | 2011-03-16 |
| BR112012005533A2 (pt) | 2016-04-26 |
| US20110217402A1 (en) | 2011-09-08 |
| IN2012DN00951A (ru) | 2015-04-10 |
| PE20121557A1 (es) | 2012-11-21 |
| AU2010293145A1 (en) | 2012-03-08 |
| MX2012002716A (es) | 2012-04-19 |
| CA2772593A1 (en) | 2011-03-17 |
| CN102575224A (zh) | 2012-07-11 |
| TWI595090B (zh) | 2017-08-11 |
| WO2011031149A1 (en) | 2011-03-17 |
| EP2475764B1 (en) | 2016-12-14 |
| MX345077B (es) | 2017-01-16 |
| JP2013504321A (ja) | 2013-02-07 |
| NZ597818A (en) | 2014-01-31 |
| MY160646A (en) | 2017-03-15 |
| ES2614929T3 (es) | 2017-06-02 |
| ECSP12011786A (es) | 2012-07-31 |
| EP2475764A1 (en) | 2012-07-18 |
| AU2010293145B2 (en) | 2016-04-14 |
| SG178230A1 (en) | 2012-03-29 |
| TW201124529A (en) | 2011-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012114190A (ru) | Полученный из пробиотиков нежизнеспособный материал для профилактики и лечения аллергии | |
| JP4728561B2 (ja) | 植物種子および微生物由来のステアリドン酸およびγ−リノレン酸を含む極性脂質リッチ画分の精製および使用方法 | |
| JP2004536059A (ja) | 微生物、遺伝的に改変された植物種子および海洋生物由来のω−３および／またはω−６高度不飽和脂肪酸を含有する極性脂質の豊富な画分の生成および使用 | |
| CN101278748B (zh) | 一种食用核桃油及脱脂核桃蛋白乳的生产方法 | |
| JP2021508343A (ja) | リゾホスファチジルコリン組成物 | |
| BRPI0618731B1 (pt) | Processo de obtenção de um óleo de abacate refinado rico em triglicerídeos, óleo suscetível de ser obtido por tal processo, seu uso e composição compreendendo tal óleo | |
| JP2002540221A5 (ru) | ||
| CN105120688A (zh) | 具有特定比率的低含量MCFAs和相对高含量不饱和脂肪酸的婴儿配方乳，及其在促进婴儿认知功能的健康建立方面的用途 | |
| JPWO2005061684A1 (ja) | 油脂組成物 | |
| JP2007503827A (ja) | 活性成分としてサルビア・スクラレア種子由来の成分を含有する組成物 | |
| WO2010010364A2 (en) | Process for the purification of oils | |
| Apostol | Studies on using hemp seed as functional ingredient in the production of functional food products. | |
| Assunção et al. | Nutritional characterization of the microalga Ruttnera lamellosa compared to Porphyridium purpureum | |
| Bowen-Forbes et al. | Fats | |
| RU2648375C2 (ru) | Детская смесь с низким содержанием жирных кислот со средней длиной цепи в определенных пропорциях и ее применение при стимуляции и/или обеспечении сбалансированного роста грудных детей | |
| JP6056093B2 (ja) | リネンオイルである脂肪酸のエチルエステルを含む健康増進食材及びその製造方法 | |
| Colla et al. | Microalgae: A new and promising source of food | |
| CA3149130A1 (en) | Multiparticulate microparticle controlled release formulation comprising combination of amino acids and phytocompound | |
| Rodrigues et al. | Omega-3 fatty acids from fish by-products: Innovative extraction and application in food and feed | |
| CN109527579A (zh) | 一种奇亚籽油制品及其制备方法和该奇亚籽油制品的应用 | |
| JP2007511222A (ja) | マンゴスチンタンパク質栄養補助食品 | |
| Dhandwal et al. | Sustainable microalgal biomass as a potential functional food and its applications in food industry: a comprehensive review | |
| JP2005206789A (ja) | 新規油脂組成物 | |
| JP4594489B2 (ja) | 特異的殺癌細胞剤及びこれを配合してなる組成物 | |
| Rahim et al. | Omega-3 Fatty Acid Retention and Oxidative Stability of Spray-Dried Chia–Fish-Oil-Prepared Microcapsules. Processes 2022, 10, 2184 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20161219 |